Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103894 | 0.75 | HTR2C (0.53) | NUDT1L3MBTL1HTR2CADORA2A | |
| SCHEMBL12559813 | 0.74 | NUDT1 (0.52) | NUDT1L3MBTL1HTR2CAXLADORA2A | |
| SCHEMBL418310 | 0.73 | NUDT1 (0.46) | NUDT1L3MBTL1HTR2CAXLADORA2A | |
| SCHEMBL12777856 | 0.72 | L3MBTL1 (0.41) | NUDT1L3MBTL1HTR2C | |
| SCHEMBL11261436 | 0.72 | L3MBTL1 (0.44) | NUDT1L3MBTL1HTR2C | |
| SCHEMBL14538474 | 0.72 | L3MBTL1 (0.44) | NUDT1L3MBTL1HTR2C | |
| SCHEMBL18248770 | 0.72 | L3MBTL1 (0.53) | NUDT1L3MBTL1HTR2CADORA2A | |
| SCHEMBL21471528 | 0.72 | L3MBTL1 (0.44) | NUDT1L3MBTL1HTR2C | |
| Hydrochloric Acid SCHEMBL30690353 | 0.72 | NUDT1 (0.45) | NUDT1L3MBTL1HTR2CAXLADORA2A | |
| SCHEMBL31240877 | 0.69 | NUDT1 (0.42) | NUDT1L3MBTL1HTR2CADORA2ADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20180370973-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-12-27 | — | — | US | disclosed |
| WO-2016101119-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106106-A2 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106106-A2 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2010069684-A1 | COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA, LTD. (BS) | 2010-06-24 | — | — | WO | disclosed |
| WO-2005085252-A1 | IMIDAZO ‘1,2-A’ PYRAZINE COMPOUNDS WHICH INTERACT WITH PROTEIN KINASES | BIOFOCUS DISCOVERY LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
| US-4408047-A | ADRENERGIC BLOCKING | MERCK & CO., INC. (US) | 1983-10-04 | — | — | US | disclosed |
| EP-0013914-B1 | PIPERAZINYL-IMIDAZO(1,2-A)PYRAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1982-12-15 | — | — | EP | disclosed |
| US-4330543-A | AS ADRENERGIC BLOCKING AGENTS | MERCK & CO., INC. (US) | 1982-05-18 | — | — | US | disclosed |
| US-4242344-A | ANOREXIGENIC, HYPOTENSIVE, ANTISMOKING, AND ANTIARRYTHMIA AGENTS; ANTIDEPRESSANTS; ANALGESICS | MERCK & CO., INC. (US) | 1980-12-30 | — | — | US | disclosed |
| US-4233301-A | ADRENERGIC BLOCKING AGENTS | MERCK & CO., INC. (US) | 1980-11-11 | — | — | US | disclosed |
| EP-0013914-A1 | Piperazinyl-imidazo(1,2-a)pyrazine derivatives, process for their preparation and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1980-08-06 | — | — | EP | disclosed |
| US-4166851-A | ADRENERGIC BLOCKING AGENTS | MERCK & CO., INC. (US) | 1979-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370973-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | NUDT1 3079/4885L3MBTL1 4347/4885HTR2C 36/4885 |
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | NUDT1 2785/4885L3MBTL1 1074/4885HTR2C 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.